The firm's over-the-counter claim submission is delayed because it has been unable to find the required number of positive cases among asymptomatic people.
The GenomeWeb Index outperformed the Dow Jones, the Nasdaq, and the Nasdaq Biotechnology Index last month, with Fulgent, Genetron, and Quidel leading the way.
Quidel expects to launch at least four new products over the next year and commented on its overall COVID-19 strategy, as well as R&D plans, M&A possibilities, and other updates.
In a letter, about two dozen researchers criticize the World Health Organization investigation into the origins of SARS-CoV-2 and call for a new inquiry, the Wall Street Journal reports.
